𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer

✍ Scribed by Germán Rodríguez; Cristina Bilbao; Raquel Ramírez; Orlando Falcón; Laureano León; Ricardo Chirino; Orlando Falcón Jr; B. Pilar Díaz; Juan F. Rivero; Manuel Perucho; B. Nicolás Díaz-Chico; Juan C. Díaz-Chico


Publisher
John Wiley and Sons
Year
2005
Tongue
French
Weight
151 KB
Volume
118
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


The human androgen receptor (AR) gene possesses 2 trinucleotide repeats of CAG and GGN in exon 1. The CAG repeat corresponds to a polyglutamine tract in the N-terminal region of the receptor, that affects its transcriptional efficiency. The GGN repeat codifies for a polyglycine tract, and affects the amount of the AR protein transcribed. The endometrium contains ARs and the androgens have antiproliferative properties in cultured endometrial cancer (EC) cells. Larger CAG repeats of the AR gene give rise to a weaker transcriptional activity and have been found to be associated with endometrial carcinogenesis. The possible involvement of CAG and GGN tracts in the progression of EC is unknown. To study that possibility, we have genotyped both CAG and GGN polymorphisms of the AR gene in tumor tissue genomic DNA from a series of 204 consecutive patients with EC, and analyzed the results with regard to the pathological features and clinical outcome of patients. We classified the alleles as S (short median). The genotype with both S-CAG repeat alleles (SS-CAG) was more common in patients diagnosed at an early stage (41.6% SS-CAG vs 22.6% SL- and LL-CAG together, p = 0.048) and in tumors that did not invade the vascular space (43.0% SS-CAG vs 26.4% SL- and LL-CAG together, p = 0.034). The genotype with SS-GGN alleles was more common in well-differentiated tumors (41.2% SS-GGN vs 25.2% LS- and LL-GGN together, p = 0.017) and in endometrioid histological subtype tumors (35.3% SS-GGN vs 13.0% SL- and LL-GGN together, p = 0.034). When the genotypes of both repeats coexisting in each tumor specimen were taken into consideration, the relationship between the SS-CAG genotype and early stage remained only in the presence of the SS-GGN genotype (43.9% vs 0%, p = 0.01). No other associations were observed. In univariate survival analysis, patients with short alleles of both repeats (SS-CAG and SS-GGN genotypes simultaneously) had a lower risk of cancer-specific death (p = 0.032, mean follow-up: 63 months). Our data suggests that short CAG or GGN repeats of the AR gene are associated with a more benign condition of traditional prognostic variables in EC.


📜 SIMILAR VOLUMES


The expansion of the CAG repeat in exon
✍ Masahiro Sasaki; Rajvir Dahiya; Seiichiro Fujimoto; Mutuo Ishikawa; Mitsuo Oshim 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 3 views

Uterine endometrial carcinoma is common among women. Several reports indicated that this cancer is influenced by androgens mediated through their receptors. The human androgen receptor gene contains a polymorphic CAG repeat in the coding region of exon 1. Other studies suggested a possible associati

Analysis of the polymorphic CAG repeat l
✍ Ewa Rajpert-De Meyts; Henrik Leffers; Gedske Daugaard; Charlotte B. Andersen; Pe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 79 KB 👁 1 views

## Abstract Changes in the length of a polymorphic trinucleotide (CAG) repeat in the androgen receptor (AR) gene, which may lead to altered transactivation of the AR gene, have been implicated to play a role in the pathogenesis of several forms of endocrine cancer and certain reproductive disorders

Amplification of the androgen receptor g
✍ Koivisto, Pasi A.; Rantala, Immo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 2 views

p53 protein expression of 30 hormone-refractory locally recurrent prostate cancers was compared with their matched untreated primary tumour specimens. In addition, androgen receptor (AR) gene amplification and p53 protein immunostaining were compared. p53 positivity increased during hormonal therapy